"The U.S. Food and Drug Administration today expanded the approved use of Opdivo (nivolumab) to treat patients with advanced (metastatic) squamous non-small cell lung cancer (NSCLC) with progression on or after platinum-based chemotherapy.
(Generic versions may still be available.)
Hepatic: Cholestatic jaundice with, rarely, hepatic necrosis and death. Hepatocellular neoplasms and peliosis hepatis have been reported in association with long-term androgenic-anabolic steroid therapy (see WARNINGS). Reversible changes in liver function tests also occur including increased bromsulphalein (BSP) retention and increases in serum bilirubin, glutamic oxaloacetic transaminase (SGOT), and alkaline phosphatase.
In both sexes: Increased or decreased libido.
Hematologic: Bleeding in patients on concomitant anticoagulant therapy.
Larynx: Deepening of the voice in women.
Metabolic/Endocrine: Decreased glucose tolerance (see PRECAUTIONS), increased serum levels of low-density lipoproteins and decreased levels of high-density lipoproteins (see PRECAUTIONS, Laboratory Tests ), increased creatine and creatinine excretion, increased serum levels of creatinine phosphokinase (CPK).
DRUG ABUSE AND DEPENDENCE
Controlled Substance Class: WINSTROL (anabolic steroids) is classified as a controlled substance under the Anabolic Steroids Control Act of 1990 and has been assigned to Schedule III.
Read the Winstrol (anabolic steroids) Side Effects Center for a complete guide to possible side effects
Last reviewed on RxList: 12/8/2004
Additional Winstrol Information
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Get the latest treatment options.